检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《南通大学学报(医学版)》2011年第2期113-114,118,共3页Journal of Nantong University(Medical sciences)
基 金:南通市社会发展资助项目(S2008057)
摘 要:目的:探讨早期使用Caspase抑制剂z-VAD-fmk对吸烟型肺气肿大鼠肺泡结构保护的机制。方法:30只清洁级SD大鼠平均随机分为对照组(A组)和肺气肿模型组(B组)和z-VAD-fmk干预组(C组)。12周后取肺组织制作石蜡切片,光镜下观察肺泡病理改变。原位缺口末端标记法(TUNEL)检测各组大鼠肺泡隔细胞凋亡指数(apoptosis index,AI),免疫组化检测肺组织中Bcl-2和Bax蛋白的表达情况。结果:12周末光镜显示:B组较C组肺气肿特征性病理改变逐渐加重,A组无肺气肿表现。各组肺泡隔细胞AI,B组与A、C组相比差异有统计学意义(P<0.05)。免疫组化显示B组Bax蛋白表达呈强阳性,而Bcl-2蛋白表达相对较弱,与A、C组比较差异有统计学意义(P<0.05)。结论:肺气肿形成初期,使用Caspase-3抑制剂z-VAD-fmk可显著上调肺组织中Bcl-2蛋白表达,抑制Bax蛋白的表达,使肺泡隔细胞凋亡减少,明显减轻肺气肿的病理改变。Objective: To investigate the mechanism of using caspase inhibitor z-VAD-fmk to protect the pulmonary alveoli structure in early stage of COPD.Methods: 30 Sprague-Dawley(SD) rats were randomly divided into three groups of 10 rats each: normal control group(A group),smoke-induced COPD group(B group) and z-VAD-fmk treatment group(C group).The rat lung tissues of 3 groups were embedded in paraffin 12 weeks later.Histopathological changes were observed by HE.TdT-mediated X-dUTP nick end labeling(TUNEL) was applied to analyze and apoptosis index(AI) was obtained.Immunohistochemistry was also applied to observe the expression of Bcl-2 and Bax.Results: 12 weeks later,there were specific pathognomonic features in B group.However,these pathognomonic features were attenuated in C group.The AI in B group was higher than that in A and C group(P0.05).Immunohistochemistry showed: Bcl-2 and Bax were expressed in lung tissue of B group,and were higher than those in A and C groups(P0.05).The expression of Bcl-2 was significantly increased after using caspase inhibitor z-VAD-fmk,but the expression of Bax was inhibited.Conclusion: In the early stage of COPD,using z-VAD-fmk can attenuate the pathognomonic features of emphysema.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28